<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01782742</url>
  </required_header>
  <id_info>
    <org_study_id>CCF-IRB 12-783</org_study_id>
    <nct_id>NCT01782742</nct_id>
  </id_info>
  <brief_title>Bexarotene Amyloid Treatment for Alzheimer's Disease</brief_title>
  <acronym>BEAT-AD</acronym>
  <official_title>A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic
      pathways relevant to Alzheimer's disease (AD) and Aβ (harmful protein) production and
      removal. The study drug &quot;bexarotene&quot; is an FDA approved anti-cancer agent but is not approved
      for use in Alzheimer's disease. Bexarotene acts as an RXR agonist that has reduced Aβ
      (harmful protein) in the brain in experimental models of Alzheimer's disease.

      This study aims to determine the safety and effect on abnormal proteins found in the brain
      (based on brain scans) of 300 mg of &quot;bexarotene&quot; administered for one month compared to
      placebo (inactive agent).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The primary study endpoint for all subjects is the change from baseline to Week 4 in amyloid burden as measured by standard uptake units regional (SUVr) on amyloid brain imaging obtained through 18F-AV-45 PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome by Genotype (ALL SUBJECTS)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers compared to E-4 non-carriers)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome by Genotype (NON ApoE4 CARRIERS)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Measures changes from baseline on treatment compared to placebo at week 4 on composite and regional Beta Amyloid burden according to ApoE genotype (NON ApoE4 CARRIERS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome by Genotype (ApoE4 CARRIERS)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HETEROZYGOTE ApoE4 CARRIERS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HOMOZYGOTE ApoE4 CARRIERS)
There are no homozygote ApoE4 carriers on the placebo arm, therefore no data can be presented on this arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in MMSE Score in ALL Subjects From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The lowest score that any particular person can get is 0 and the highest score is 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 85 (worse). A positive change indicates cognitive worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The CDR is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). Higher score means more severe dementia rating. The score is based on interviews with the participant and study partner, using a structured interview that assesses six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NPI Scores in ALL Subjects From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The NPI is a well validated, reliable, multi-item instrument to assess psychopathology in AD based on interview with the study partner. The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score and the score for each subscale are the product of severity and frequency. Overall score range from 0 meaning no disturbance to 144 meaning severe disturbance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The ADCS-ADL is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. Overall score range from 0 meaning fully independent to 78 meaning fully dependent on assistance for activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes (non ApoE4 carriers)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in non ApoE4 Carriers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Bexarotene treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexarotene</intervention_name>
    <description>Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
    <arm_group_label>Bexarotene treatment Arm</arm_group_label>
    <other_name>Targretin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 50 to 90 of age inclusive.

          -  Diagnosis of probable AD according to National Institute of Neurological and
             Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders
             Association (NINCDS-ADRDA) criteria.

          -  Willing and able to provide informed consent by either the subject or subject's legal
             representative.

          -  Willing and able to comply with study visits, treatment plan, laboratory tests, brain
             imaging and other procedures.

          -  Subjects must have a positive 18f-AV-45 PET scan as determined by a qualified rater.

          -  Mini-Mental State Examinations (MMSE) score between 10-20 inclusive.

          -  Must have a study partner who is able and willing to comply with all required study
             procedures.

          -  Females must be postmenopausal.

          -  Have at least eight years of education and should have previously (in pre-AD
             condition) been capable of reading, writing, and communicating effectively with others
             in English.

          -  If receiving therapy with a cholinesterase inhibitor and/or memantine, the dose of
             these agents has been stable for at least 4 weeks prior to randomization

          -  Normal laboratory findings at baseline including CBC, chemistry panel, serum lipids,
             liver functions, TSH, and vitamin B12.

          -  Must consent to ApoE genotyping

        Exclusion Criteria:

          -  Any clinically relevant neurological disorder capable of producing a dementia syndrome
             including Parkinson's disease, stroke, vascular dementia, dementia with Lewy bodies,
             frontotemporal dementia and others.

          -  4 or more micro-hemorrhages (amyloid-related imaging abnormalities - hemorrhage type
             (ARIA-H) on baseline MRI or any evidence of amyloid-related imaging abnormalities -
             effusion type (ARIA-E) (Sperling et al, 2011).

          -  History of malignancy within the past five years with the exception of basal cell or
             squamous cell cancer, in-situ cervical cancer, or localized prostate cancer.

          -  History of seizure in the past three years prior to randomization

          -  Any contraindication of having brain MRI

          -  Any contraindication of having PET (inability to lie flat and still for the duration
             of the scan, intolerance to previous PET such as hypersensitivity reaction to PET
             ligand or imaging agent)

          -  The subject has any unstable medical illness including hypertension, congestive heart
             failure, chronic obstructive pulmonary disease, renal failure, liver failure or other
             organ compromise.

          -  Other clinically important abnormality on vital signs, physical examination,
             neurologic examination, laboratory results, or electrocardiogram (ECG) examination
             (e.g. Atrial fibrillation) that could compromise the study or be detrimental to the
             subject.

          -  The subject has received bexarotene previously.

          -  The subject has an allergy to bexarotene.

          -  Has had a PET scan in the past 12 months.

          -  Has had radiotherapy in the past year.

          -  Have participated in an investigational drug or device study within 30 days prior to
             Visit 2.

          -  Have been treated with immunomodulators to treat AD (vaccines, antibodies etc) within
             6 months prior to visit 2

          -  Unable to swallow uncrushed oral medication in capsule form

          -  Have any condition or reason that, in the opinion of the investigator, which could
             interfere with the ability of the patients to participate or complete the trials, or
             places the patient at undue risk or complicates the interpretation of safety or
             efficacy data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Cummings, MD, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <results_first_submitted>February 10, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2016</results_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild to Moderate Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted in the United States at one site. The first participant was enrolled in April 2013.</recruitment_details>
      <pre_assignment_details>49 participants were screened, 29 were screen failures, 20 participants were randomized to treatment. 1 was withdrawn after Week 4 treatment. Inclusion and exclusion criteria was the strict basis for eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bexarotene Treatment Arm</title>
          <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bexarotene Treatment Arm</title>
          <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age at Screening</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age at Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.9" spread="6.6"/>
                    <measurement group_id="B2" value="78.1" spread="8.0"/>
                    <measurement group_id="B3" value="75.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Race - Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race - African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years of Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" spread="4.9"/>
                    <measurement group_id="B2" value="12.3" spread="3.3"/>
                    <measurement group_id="B3" value="14.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years of Cognitive Symptoms</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="1.9"/>
                    <measurement group_id="B2" value="2.8" spread="0.96"/>
                    <measurement group_id="B3" value="4.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MMSE total score</title>
          <description>The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The lowest score that any particular person can get is 0 and the highest score is 30.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.7" lower_limit="8" upper_limit="23"/>
                    <measurement group_id="B2" value="17.0" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="B3" value="14.4" lower_limit="8" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADAS-Cog score</title>
          <description>The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 85 (worse). A positive change indicates cognitive worsening.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" lower_limit="35" upper_limit="65"/>
                    <measurement group_id="B2" value="40.3" lower_limit="28" upper_limit="54"/>
                    <measurement group_id="B3" value="48.0" lower_limit="28" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CDR score</title>
          <description>The CDR is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). Higher score means more severe dementia rating. The score is based on interviews with the participant and study partner, using a structured interview that assesses six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="B2" value="1.1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="B3" value="1.4" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NPI score</title>
          <description>The NPI is a well validated, reliable, multi-item instrument to assess psychopathology in AD based on interview with the study partner. The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score and the score for each subscale are the product of severity and frequency. Overall score range from 0 meaning no disturbance to 144 meaning severe disturbance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" lower_limit="0" upper_limit="29"/>
                    <measurement group_id="B2" value="7.0" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="B3" value="8.4" lower_limit="0" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NPI Distress Score</title>
          <description>NPI distress score measures the distress that the caregiver experiences during the previous 4 weeks from the assessment date. Distress score is measured on a scale between 0 to 5. 0 being not at all distressed to 5 very severely or extremely distressed. The scores for all 12 domains are added up becomes the total score. 0 means no caregiver distress and 60 means extreme caregiver distress.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="0" upper_limit="35"/>
                    <measurement group_id="B2" value="4.3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B3" value="6.1" lower_limit="0" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADCS-ADL score</title>
          <description>The ADCS-ADL is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. Overall score range from 0 meaning fully independent to 78 meaning fully dependent on assistance for activities of daily living.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" lower_limit="34" upper_limit="77"/>
                    <measurement group_id="B2" value="64.5" lower_limit="37" upper_limit="76"/>
                    <measurement group_id="B3" value="55.9" lower_limit="34" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ApoE4 Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-carriers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heterozygotes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homozygotes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain</title>
        <description>The primary study endpoint for all subjects is the change from baseline to Week 4 in amyloid burden as measured by standard uptake units regional (SUVr) on amyloid brain imaging obtained through 18F-AV-45 PET</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain</title>
          <description>The primary study endpoint for all subjects is the change from baseline to Week 4 in amyloid burden as measured by standard uptake units regional (SUVr) on amyloid brain imaging obtained through 18F-AV-45 PET</description>
          <units>SUVr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.06" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.05" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MMSE Score in ALL Subjects From Baseline to Week 4</title>
        <description>The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The lowest score that any particular person can get is 0 and the highest score is 30.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MMSE Score in ALL Subjects From Baseline to Week 4</title>
          <description>The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The lowest score that any particular person can get is 0 and the highest score is 30.</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" lower_limit="-0.783" upper_limit="2.283"/>
                    <measurement group_id="O2" value="1.750" lower_limit="-1.316" upper_limit="4.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.428</ci_lower_limit>
            <ci_upper_limit>2.428</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4</title>
        <description>The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 85 (worse). A positive change indicates cognitive worsening.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4</title>
          <description>The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 85 (worse). A positive change indicates cognitive worsening.</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.375" lower_limit="-2.153" upper_limit="2.903"/>
                    <measurement group_id="O2" value="-0.250" lower_limit="-5.307" upper_limit="4.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.625</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.029</ci_lower_limit>
            <ci_upper_limit>6.279</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4</title>
        <description>The CDR is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). Higher score means more severe dementia rating. The score is based on interviews with the participant and study partner, using a structured interview that assesses six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4</title>
          <description>The CDR is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). Higher score means more severe dementia rating. The score is based on interviews with the participant and study partner, using a structured interview that assesses six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.000" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>0.000</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NPI Scores in ALL Subjects From Baseline to Week 4</title>
        <description>The NPI is a well validated, reliable, multi-item instrument to assess psychopathology in AD based on interview with the study partner. The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score and the score for each subscale are the product of severity and frequency. Overall score range from 0 meaning no disturbance to 144 meaning severe disturbance</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NPI Scores in ALL Subjects From Baseline to Week 4</title>
          <description>The NPI is a well validated, reliable, multi-item instrument to assess psychopathology in AD based on interview with the study partner. The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score and the score for each subscale are the product of severity and frequency. Overall score range from 0 meaning no disturbance to 144 meaning severe disturbance</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.625" lower_limit="-6.783" upper_limit="1.533"/>
                    <measurement group_id="O2" value="-2.250" lower_limit="-10.570" upper_limit="6.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.375</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.674</ci_lower_limit>
            <ci_upper_limit>8.924</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4</title>
        <description>The ADCS-ADL is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. Overall score range from 0 meaning fully independent to 78 meaning fully dependent on assistance for activities of daily living</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4</title>
          <description>The ADCS-ADL is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD (Galasko et al., 1997). Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. Overall score range from 0 meaning fully independent to 78 meaning fully dependent on assistance for activities of daily living</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.938" lower_limit="-4.861" upper_limit="0.986"/>
                    <measurement group_id="O2" value="-6.500" lower_limit="-12.350" upper_limit="-0.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.563</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.975</ci_lower_limit>
            <ci_upper_limit>11.100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome by Genotype (ALL SUBJECTS)</title>
        <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers compared to E-4 non-carriers)</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Change om composite and regional Beta Amyloid burden according to ApoE genotype on ALL SUBJECTS</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome by Genotype (ALL SUBJECTS)</title>
          <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers compared to E-4 non-carriers)</description>
          <population>Change om composite and regional Beta Amyloid burden according to ApoE genotype on ALL SUBJECTS</population>
          <units>SUVr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frontal Medial Orbital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.043" lower_limit="-0.081" upper_limit="-0.006"/>
                    <measurement group_id="O2" value="-0.021" lower_limit="-0.096" upper_limit="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.040" lower_limit="-0.080" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.018" lower_limit="-0.061" upper_limit="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parietal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" lower_limit="-0.034" upper_limit="0.027"/>
                    <measurement group_id="O2" value="0.044" lower_limit="-0.018" upper_limit="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.017" lower_limit="-0.065" upper_limit="0.031"/>
                    <measurement group_id="O2" value="0.044" lower_limit="-0.052" upper_limit="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precuneus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027" lower_limit="-0.069" upper_limit="0.014"/>
                    <measurement group_id="O2" value="0.040" lower_limit="-0.043" upper_limit="0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temporal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038" lower_limit="-0.075" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.016" lower_limit="-0.059" upper_limit="0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome by Genotype (NON ApoE4 CARRIERS)</title>
        <description>Measures changes from baseline on treatment compared to placebo at week 4 on composite and regional Beta Amyloid burden according to ApoE genotype (NON ApoE4 CARRIERS)</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Change in composite and regional Beta Amyloid Burden on non-ApoE4 carriers</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome by Genotype (NON ApoE4 CARRIERS)</title>
          <description>Measures changes from baseline on treatment compared to placebo at week 4 on composite and regional Beta Amyloid burden according to ApoE genotype (NON ApoE4 CARRIERS)</description>
          <population>Change in composite and regional Beta Amyloid Burden on non-ApoE4 carriers</population>
          <units>SUVr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.097" lower_limit="-0.155" upper_limit="-0.040"/>
                    <measurement group_id="O2" value="0.047" lower_limit="-0.019" upper_limit="0.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Medial Orbital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.076" lower_limit="-0.146" upper_limit="-0.007"/>
                    <measurement group_id="O2" value="0.005" lower_limit="-0.075" upper_limit="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.096" lower_limit="-0.166" upper_limit="-0.026"/>
                    <measurement group_id="O2" value="0.048" lower_limit="-0.034" upper_limit="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parietal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.068" lower_limit="-0.107" upper_limit="-0.029"/>
                    <measurement group_id="O2" value="0.065" lower_limit="0.020" upper_limit="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.113" lower_limit="-0.180" upper_limit="-0.046"/>
                    <measurement group_id="O2" value="0.074" lower_limit="-0.004" upper_limit="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precuneus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.127" lower_limit="-0.188" upper_limit="-0.066"/>
                    <measurement group_id="O2" value="0.062" lower_limit="-0.008" upper_limit="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temporal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.104" lower_limit="-0.162" upper_limit="-0.045"/>
                    <measurement group_id="O2" value="0.031" lower_limit="-0.037" upper_limit="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome by Genotype (ApoE4 CARRIERS)</title>
        <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers)</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Change in composite and regional Beta Amyloid burden on ApoE4 carriers</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome by Genotype (ApoE4 CARRIERS)</title>
          <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (E-4 carriers)</description>
          <population>Change in composite and regional Beta Amyloid burden on ApoE4 carriers</population>
          <units>SUVr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" lower_limit="-0.041" upper_limit="0.031"/>
                    <measurement group_id="O2" value="-0.048">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Medial Orbital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033" lower_limit="-0.074" upper_limit="0.009"/>
                    <measurement group_id="O2" value="-0.099">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" lower_limit="-0.062" upper_limit="0.019"/>
                    <measurement group_id="O2" value="-0.069">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parietal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" lower_limit="-0.013" upper_limit="0.050"/>
                    <measurement group_id="O2" value="-0.019">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" lower_limit="-0.035" upper_limit="0.065"/>
                    <measurement group_id="O2" value="-0.044">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precuneus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" lower_limit="-0.031" upper_limit="0.043"/>
                    <measurement group_id="O2" value="-0.027">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temporal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" lower_limit="-0.055" upper_limit="0.024"/>
                    <measurement group_id="O2" value="-0.030">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)</title>
        <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HETEROZYGOTE ApoE4 CARRIERS)</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Change in composite and regional Beta Amyloid burden on Heterozygote ApoE4 carriers</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)</title>
          <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HETEROZYGOTE ApoE4 CARRIERS)</description>
          <population>Change in composite and regional Beta Amyloid burden on Heterozygote ApoE4 carriers</population>
          <units>SUVr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" lower_limit="-0.037" upper_limit="0.008"/>
                    <measurement group_id="O2" value="-0.048">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Medial Orbital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.061" lower_limit="-0.090" upper_limit="-0.033"/>
                    <measurement group_id="O2" value="-0.099">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.048" lower_limit="-0.080" upper_limit="-0.016"/>
                    <measurement group_id="O2" value="-0.069">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parietal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" lower_limit="0.009" upper_limit="0.058"/>
                    <measurement group_id="O2" value="-0.019">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" lower_limit="-0.035" upper_limit="0.022"/>
                    <measurement group_id="O2" value="-0.044">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precuneus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" lower_limit="-0.021" upper_limit="0.032"/>
                    <measurement group_id="O2" value="-0.027">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temporal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" lower_limit="-0.041" upper_limit="0.020"/>
                    <measurement group_id="O2" value="-0.030">With 1 placebo patient, variability within the group cannot measured effectively</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)</title>
        <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HOMOZYGOTE ApoE4 CARRIERS)
There are no homozygote ApoE4 carriers on the placebo arm, therefore no data can be presented on this arm.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Change in composite and regional Beta Amyloid burden on Homozygote ApoE4 carriers.
There are no homozygote ApoE4 carriers on the placebo arm, therefore no data can be presented on this arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)</title>
          <description>This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden according to ApoE genotype (HOMOZYGOTE ApoE4 CARRIERS)
There are no homozygote ApoE4 carriers on the placebo arm, therefore no data can be presented on this arm.</description>
          <population>Change in composite and regional Beta Amyloid burden on Homozygote ApoE4 carriers.
There are no homozygote ApoE4 carriers on the placebo arm, therefore no data can be presented on this arm.</population>
          <units>SUVr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" lower_limit="-0.066" upper_limit="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Medial Orbital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" lower_limit="-0.077" upper_limit="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" lower_limit="-0.067" upper_limit="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parietal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="-0.054" upper_limit="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" lower_limit="-0.059" upper_limit="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precuneus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" lower_limit="-0.065" upper_limit="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temporal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" lower_limit="-0.096" upper_limit="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)</title>
        <description>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes in ALL SUBJECTS. There were only a total of 17 subjects who were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 3 subjects were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)</title>
          <description>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes</description>
          <population>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes in ALL SUBJECTS. There were only a total of 17 subjects who were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 3 subjects were unsuccessful.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta Amyloid 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.186" lower_limit="-3.673" upper_limit="18.045"/>
                    <measurement group_id="O2" value="-5.330" lower_limit="-24.910" upper_limit="14.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Amyloid 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.585" lower_limit="-0.044" upper_limit="1.213"/>
                    <measurement group_id="O2" value="-0.900" lower_limit="-2.033" upper_limit="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)</title>
        <description>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes (non ApoE4 carriers)</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels in non ApoE4 carriers. Of the 7 total subjects who were non-ApoE carriers, only 6 subjects were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 1 subject were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)</title>
          <description>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels comprised in secondary biomarker outcomes (non ApoE4 carriers)</description>
          <population>Change from baseline to week 4 in beta amyloid1-40 and beta amyloid1-42 serum levels in non ApoE4 carriers. Of the 7 total subjects who were non-ApoE carriers, only 6 subjects were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 1 subject were unsuccessful.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta Amyloid 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.503" lower_limit="-22.840" upper_limit="15.836"/>
                    <measurement group_id="O2" value="-8.550" lower_limit="-27.890" upper_limit="10.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Amyloid 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.293" lower_limit="-0.873" upper_limit="1.460"/>
                    <measurement group_id="O2" value="-1.127" lower_limit="-2.293" upper_limit="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects</title>
        <description>This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in all subjects</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>There were only a total of 17 subjects who were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 3 subjects were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects</title>
          <description>This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in all subjects</description>
          <population>There were only a total of 17 subjects who were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 3 subjects were unsuccessful.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="-0.007" upper_limit="0.008"/>
                    <measurement group_id="O2" value="-0.005" lower_limit="-0.019" upper_limit="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.006</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers</title>
        <description>This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in non ApoE4 Carriers</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Of the 7 total subjects who were non-ApoE carriers, only 6 subjects were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 1 subject were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexarotene</title>
            <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers</title>
          <description>This measures the change in the ratio of Beta Amyloid 42 to Beta Amyloid 40 from baseline to week 4 in non ApoE4 Carriers</description>
          <population>Of the 7 total subjects who were non-ApoE carriers, only 6 subjects were able to provide adequate blood sample for this serum biomarker analysis. Attempts for blood sample procurement for the other 1 subject were unsuccessful.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" lower_limit="-0.016" upper_limit="0.026"/>
                    <measurement group_id="O2" value="-0.005" lower_limit="-0.026" upper_limit="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the time the participants signed the informed consent forms to the Post-Treatment Follow Up Visit approximating to 4 months of time when adverse events were captured</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bexarotene Treatment Arm</title>
          <description>75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Bexarotene: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated cholesterol level</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated triglyceride levels</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister on toe</sub_title>
                <description>Participant had a blister on 2nd toe of left foot</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size of this trial is small. There was 1 participant withdrawal due to adverse event. Primary outcome measures were completed by all 20 participants as anticipated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey Cummings, MD, ScD</name_or_title>
      <organization>Cleveland Clinic Lou Ruvo Center for Brain Health</organization>
      <phone>702.483.6029</phone>
      <email>cumminj@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

